Nasdaq Tumbles 2%; Pliant Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading following the release of jobs report on Friday.
Why These Casino Stocks Are Moving Lower, Here’s 45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase…
Freeline To Present New Clinical Data For FLT180A In Hemophilia B At International Society On Thrombosis And Haemostasis Congress
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Freeline Therapeutics FY21 EPS $(3.93) Up From $(6.81) YoY
Freeline Therapeutics (NASDAQ:FRLN) reported quarterly losses of $(3.93) per share. This is a 42.29 percent increase over losses of $(6.81) per share from the same period last year.
Freeline Announces Updated Development Plan And Timelines For FLT190 For People With Fabry Disease
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the “Company” or “Freeline”), today announced an updated clinical development plan and timelines for FLT190 for people with Fabry disease, a rare,
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly’s Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: